LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Biotechnology?src=hash" target="_blank"gt;#Biotechnologylt;/agt;–The global chemotherapy treatment market is expected to post a CAGR of
close to 3% during the period 2019-2023, according to the latest market
research report by Technavio.
A key factor driving the growth of the global chemotherapy treatment
market is the increasing prevalence of various types of cancers. Cancer
has become the second-leading cause of death and the most widely
prevalent disease worldwide. Some of the most common cancers include
lung and bronchus cancer, breast cancer, prostate cancer, colon and
rectum cancer, melanoma of the skin, bladder cancer, leukemia,
pancreatic cancer, and liver cancer. Chemotherapy is used as first-line
therapy to treat these cancers. Moreover, the market has witnessed
recent approvals of chemotherapy agents by regulatory authorities in
different regions. For instance, the US FDA gave its approval for
TECENTRIQ in combination with carboplatin and etoposide for first-line
treatment of adult patients with lung cancer. Therefore, the increasing
prevalence of various types of cancers and recent approvals of
chemotherapeutics will significantly impact the growth of the
chemotherapy treatment market during the forecast period.
As per Technavio, the development of combination therapies will have a
positive impact on the market and contribute to its growth significantly
over the forecast period. This global
chemotherapy treatment market 2019-2023 research report
also analyzes other important trends and market drivers that will affect
market growth over 2019-2023.
Global chemotherapy treatment market:
Development of combination therapies
The chemotherapy market is witnessing the development of combination
therapies owing to the increase in drug resistance. Combination
therapies can reduce drug resistance as tumors are less likely to have
resistance to multiple drugs. Moreover, there are several combination
therapies that are under development to treat various cancers. For
instance, Eli Lilly is testing an investigational drug, necitumumab
(IMC-11F8), with gemcitabine-cisplatin chemotherapy. Several vendors are
also focusing on the development of combination therapies with
chemotherapy drugs along with targeted therapies. Such developments will
significantly impact the growth of the chemotherapy treatment market
during the forecast period.
“Apart from the development of combination therapies and increasing
prevalence of various types of cancer, factors such as the recent
approvals of chemotherapeutics to treat cancer, and the availability of
drugs to treat the side-effects of chemotherapy will significantly
impact the growth of the solar PV services market during the forecast
period” says a senior research analyst at Technavio.
Global chemotherapy treatment market:
This market research report segments the global chemotherapy treatment
market by drug class (antimetabolites, plant derivatives, cytotoxic
antibiotics, alkylating agents, and others) and geographic regions
(North America, Europe, Asia, and ROW).
The North American region led the chemotherapy treatment market in 2018,
followed by Europe, Asia, and ROW respectively. The market growth in
North America can be attributed to the growing prevalence of cancer, the
strong preference of vendors, and the availability of chemotherapeutics
to treat cancer.
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market size and forecast
Five Forces Analysis
- Regional comparison
- Key leading countries
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
at [email protected].
Media & Marketing Executive
+1 844 364 1100
UK: +44 203 893 3200